Webcast Alert: Aastrom to Report Fourth Quarter and Year-End 2011 Operating Results on Monday, March 12, 2012
10 March 2012 - 3:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, announces the
following webcast:
What: |
Aastrom Biosciences, Inc., Fourth Quarter and
Year-End 2011 Operating Results |
|
|
When: |
Monday, March 12, 2012 at 4:30 pm (EDT) |
|
|
Where: |
http://investors.aastrom.com/events.cfm |
|
|
How: |
|
|
-- The conference call will be available live
in the Investors section of the Aastrom website at
http://investors.aastrom.com/events.cfm. Please access the site at
least 15 minutes prior to the scheduled start time in order to
download the required audio software if necessary. |
|
|
|
-- To participate in the live call by
telephone, please call (877) 312-5881 and reference Aastrom
Biosciences fourth quarter 2011 investor conference call. If
calling from outside the U.S., please use the international phone
number (253) 237-1173. The conference ID is 48237558. |
If you are unable to participate during the live call, the
webcast will be available
at http://investors.aastrom.com/events.cfm until March 12,
2013. A replay of the call will also be available until 11:59 pm
(EDT) on March 16, 2012 by calling (855) 859-2056, or from outside
the U.S. at (404) 537-3406. The conference ID is 48237558.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including a
Phase 3 clinical program to study patients with critical limb
ischemia and a planned Phase 2b clinical trial in patients with
ischemic dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com. For more information on
the pivotal REVIVE Phase 3 clinical trial, please visit the trial
website at www.revivecli.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements,
including, without limitation, statements concerning clinical trial
plans and progress, objectives and expectations, clinical activity
timing, intended product development, the performance and
contribution of certain individuals and expected timing of
collecting and analyzing treatment data, all of which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Bill Berry
Berry & Company
bberry@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024